| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 816801 | 25 ug | $245 | ||
| 816802 | 100 ug | $595 |
| Application | FC |
|---|---|
| Format | Liquid, PE |
| Expression Host | CHO |
| Target Name | CD80, B7-1, B7, BB1 |
| Species | Human |
| Sources | Recombinant Human B7-1 (CD80) (Val35-Asn242) with C-terminus His-tag is expressed in CHO cell and conjugated to PE. |
| Accession Number | Q68D85 |
| Molecular Weight | The protein has a predicted molecular weight of 25.5 kDa. Under DTT-reducing conditions, it migrates at approximately 45 kDa on SDS-PAGE prior to conjugation. |
| Affinity Tag | C-His |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months. |
B7-1, also known as CD80, is a cell surface glycoprotein in the immunoglobulin superfamily, expressed on activated B cells, macrophages, and dendritic cells. It interacts with the costimulatory receptors CD28 and CTLA-4 on T cells, playing a pivotal role in regulating T cell activation, tolerance, cytokine production, and the generation of cytotoxic T lymphocytes. Through its interactions with CD28 and CTLA-4, CD80 is involved in both enhancing and inhibiting immune responses, thereby maintaining immune balance. This B7/CD28/CTLA-4 pathway is crucial for controlling immune function and is considered a promising target for therapeutic interventions in autoimmune diseases and cancer.
PE conjugated Human B7-1 (CD80) (C-His) TDS
Have a product or application question? Consult our FAQs or contact us.
